Pierre Fabre and EORTC open a large Phase III clinical study in the adjuvant setting of stage IIB-C melanoma
- Written by PR Newswire
- First study conducted in the adjuvant setting with a combination of BRAF and MEK inhibitors in high-risk stage II BRAF V600E/K-mutant cutaneous melanoma
- A global partnership between EORTC and Pierre Fabre to advance research in melanoma
CASTRES, France and BRUSSELS, May 24, 2022 /PRNewswire/ -- Pierre Fabre and the European Organisation for Research...